Market closed
DexCom/$DXCM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About DexCom
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Ticker
$DXCM
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
10,250
Website
DexCom Metrics
BasicAdvanced
$26B
46.95
$1.42
1.29
-
Price and volume
Market cap
$26B
Beta
1.29
52-week high
$139.24
52-week low
$57.52
Average daily volume
4.6M
Financial strength
Current ratio
1.467
Quick ratio
1.223
Long term debt to equity
61.923
Total debt to equity
120.275
Interest coverage (TTM)
31.58%
Management effectiveness
Return on assets (TTM)
6.15%
Return on equity (TTM)
27.63%
Valuation
Price to earnings (TTM)
46.951
Price to revenue (TTM)
6.525
Price to book
12.42
Price to tangible book (TTM)
13.22
Price to free cash flow (TTM)
41.725
Growth
Revenue change (TTM)
11.34%
Earnings per share change (TTM)
9.35%
3-year revenue growth (CAGR)
18.10%
3-year earnings per share growth (CAGR)
38.81%
What the Analysts think about DexCom
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for DexCom stock.
DexCom Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
DexCom Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
DexCom News
AllArticlesVideos
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
GlobeNewsWire·2 days ago
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
Business Wire·6 days ago
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for DexCom stock?
DexCom (DXCM) has a market cap of $26B as of April 25, 2025.
What is the P/E ratio for DexCom stock?
The price to earnings (P/E) ratio for DexCom (DXCM) stock is 46.95 as of April 25, 2025.
Does DexCom stock pay dividends?
No, DexCom (DXCM) stock does not pay dividends to its shareholders as of April 25, 2025.
When is the next DexCom dividend payment date?
DexCom (DXCM) stock does not pay dividends to its shareholders.
What is the beta indicator for DexCom?
DexCom (DXCM) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.